Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes.
Low doses of megestrol acetate are frequently used for treatment of hot flashes in men having androgen ablation for prostate cancer. We report a case in which megestrol acetate (20 mg bid) was administered for symptomatic control of hot flashes in a medically castrated patient with prostate cancer. The patient was subsequently noted to have a rising prostate-specific antigen (PSA) level. Megestrol acetate administration was discontinued, and the PSA level declined. These data indicate that even the low doses of megestrol acetate used for control of hot flashes can be associated with PSA increases in some patients with prostate cancer.
Sartor
O
O
Department of Urology, Louisiana State University Medical Center, Shreveport 71130, USA.
Eastham
J A
JA
D000368:Aged; D018757:GABA Modulators / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D019584:Hot Flashes / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000009:adverse effects*; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy
D018757:GABA Modulators; D007987:Gonadotropin-Releasing Hormone; D017430:Prostate-Specific Antigen; D019290:Megestrol Acetate